Literature DB >> 696340

Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo.

A Forman, K E Andersson, L Henriksson, T Rud, U Ulmsten.   

Abstract

Smooth muscle preparations of the urethra, bladder, and ureter were obtained from patients undergoing operations for various urological disorders. The urethral preparations were contracted by noradrenaline (0.1-3 microgram . ml-1), prostaglandin F2alpha (1-10 microgram . ml-1), and potassium (127 mM), the bladder preparations by carbacholine (0.004-1 microgram . ml-1), prostaglandin F2alpha (1-10 microgram . ml-1), potassium (127 mM), and barium chloride (3 mM), and the ureter preparations by potassium (127 mM), and barium chloride (3 mM). Irrespective of the mode of activation, pretreatment with nifedipine (0.1 microgram . ml-1) for 10 min. reduced the responses. Nifedipine also relaxed preparations contracted by the contractile agents used. In 19 female patients, aged 20 to 73 years, undergoing investigation because of urgency and/or urge incontinence, simultaneous urethrocystometry at rest was performed before and after oral administration of 20 to 40 mg nifedipine. Bladder capacity and residual urine were also determined. Nifedipine did not affect the pressures within the bladder and urethra, nor did it increase the bladder capacity. However, after nifedipine intake there was a statistically significant increase in residual urine. The results suggest that nifedipine can inhibit contractile activity induced by drugs with different modes of action; the drug does not affect the tone in bladder and urethra.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 696340     DOI: 10.1111/j.1600-0773.1978.tb02244.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  14 in total

1.  Adjunctive therapy to promote stone passage.

Authors:  Geoffrey R Nuss; Judson D Rackley; Dean G Assimos
Journal:  Rev Urol       Date:  2005

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Effects of selective inhibitors of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) on the spontaneous myogenic contractions in the upper urinary tract of the guinea-pig and rat.

Authors:  M E Davidson; R J Lang
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  Effects of papaverine on human isolated bladder muscle.

Authors:  L Hertle; H Nawrath
Journal:  Urol Res       Date:  1990

5.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Receptor binding studies of the flavone, REC 15/2053, and other bladder spasmolytics.

Authors:  G A Abbiati; R Ceserani; D Nardi; C Pietra; R Testa
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

7.  Effects of verapamil and sodium nitroprusside on acetylcholine-induced contraction of the rabbit detrusor muscle.

Authors:  M Gotoh; A Kondo; M Hassouna; M M Elhilali
Journal:  Urol Res       Date:  1987

Review 8.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

9.  Efficacy of nifedipine in the treatment of angina pectoris and chronic airways obstruction.

Authors:  S S Jaiprakash; J N Sahay; S S Chatterjee; G MacDonald
Journal:  Postgrad Med J       Date:  1980-09       Impact factor: 2.401

Review 10.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.